Dosage and administration method of Ivonescimab injection

Ivonescimab injection (Ivonescimab) is a new type of immunotherapy drug that has been approved for use in combination with pemetrexed (pemetrexed) and carboplatin (carboplatin). It is mainly used for treatment Patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, particularly those who have progressed after treatment with tyrosine kinase inhibitors (TKIs).

In terms of usage and dosage, the recommended dose of ivocilimab injection is20 mg/kg. The drug should be given intravenously every three weeks, with each injection lasting 60 minutes to ensure effective absorption of the drug and reduce the risk of adverse reactions. It should be noted when using medication that evocilimab should be administered first, followed by chemotherapy, and there needs to be an interval of at least 30 minutes between the two. This order of administration helps improve the overall effectiveness and safety of treatment.

During the use of the drug, some atypical efficacy reactions may occur. For example, in the early months of treatment, the tumor may temporarily increase or new lesions may appear, and then gradually shrink. In this case, if the patient's clinical symptoms remain stable or continue to decrease, even if there is preliminary evidence of disease progression on imaging, based on the patient's overall clinical benefit, physicians may consider continuing evocilimab until further disease progression is confirmed.

In order to ensure the effectiveness of treatment and the safety of patients, clinicians must strictly follow the recommended dosage and usage when prescribing, and adjust the medication regimen according to the patient's actual condition. In addition, patients' condition changes and related adverse reactions must be regularly monitored so that timely intervention and adjustments can be made.

In short, the specific administration method and dosage setting of ivocilimab injection are based on its clinical trial results and consideration of the best efficacy for patients. When implementing treatment, medical staff should fully understand the usage specifications of the drug to ensure that patients can receive the best quality medical services.

Reference materials:https://www.akesobio.com/en/media/akeso-news/240908/